A competitor’s pipeline is not a secret. It is a public record, filed in tranches at the USPTO, EPO, and […]

GW Pharmaceuticals spent roughly two decades and hundreds of millions of dollars turning cannabis extracts into regulated pharmaceuticals. When Jazz

The pharmaceutical industry spent the last decade automating drug discovery. Billions went into generative chemistry platforms, phenomic screening systems, and

The standard Paragraph IV playbook was written for atorvastatin and metformin, not for drugs prescribed to 800 patients nationwide. When

The pharmaceutical vendor ecosystem — CROs, CDMOs, biomarker platform providers, data analytics firms, and laboratory services companies — has spent

The FDA’s Purple Book is supposed to be the authoritative public registry for biologic drug patents in the United States.

How combination patent architecture protects pharmaceutical revenue after composition-of-matter expiry — and what the post-Teva v. Amneal landscape means for

When a small-molecule drug loses its composition-of-matter patent, the conventional story is that the clock runs out and generic manufacturers

Two protection systems govern pharmaceutical market exclusivity in the United States. One is a private intellectual property right, contested in